Study Finds Shingles Vaccine Linked to Reduced Dementia Risk

New research linking shingles vaccination and lower dementia diagnoses is strengthening—though experts say more work is needed to confirm cause and explain why.​

Shingles vaccine reduced dementia risk in a large natural experiment analysis from Wales, with researchers estimating about a one-fifth relative reduction in new dementia diagnoses over seven years among vaccinated adults. Separate research in the US has also found that the newer recombinant shingles vaccine (Shingrix) was associated with a lower chance of a dementia diagnosis over about six years of follow-up. The findings arrive as dementia remains a major global health burden, affecting tens of millions of people worldwide.​

What the new Wales study found

Researchers reported evidence consistent with a dementia-preventing or dementia-delaying effect from shingles (herpes zoster) vaccination by using a policy-driven eligibility cutoff based on exact date of birth in Wales. In the study’s main estimate, receiving the live-attenuated zoster vaccine reduced the probability of a new dementia diagnosis over seven years by 3.5 percentage points, corresponding to a 20.0% relative reduction (with a 95% confidence interval of 6.5% to 33.4%). The authors framed this approach as more resistant to typical healthy user bias than standard observational comparisons, because eligibility hinged on birthdate rather than personal choice alone.​

One notable detail: the published analysis reported stronger protective effects among women than men, though the study was not designed to fully explain why that difference might exist. The paper also connects its rationale to broader scientific interest in whether neurotropic herpesviruses and immune off-target effects could play roles in dementia risk.​

Evidence from Shingrix (recombinant vaccine)

A separate, widely discussed line of research has focused on the recombinant shingles vaccine, commonly known as Shingrix, which is used in many countries today. In a Nature Medicine paper, researchers reported that the recombinant vaccine was associated with a significantly lower risk of dementia during the six years after vaccination, compared with the older live vaccine. The same paper reported an estimated 164 additional days lived without a dementia diagnosis among those later affected—an effect the authors described as clinically meaningful.​

These results matter practically because the older live vaccine (Zostavax) is no longer available in the United States, while Shingrix is the routinely recommended option. Taken together, the Wales results (more quasi-experimental) and the Shingrix analyses (large-scale real-world data) are helping researchers triangulate whether the association might be partly causal, and whether vaccine type matters.​

Why researchers think a shingles shot could matter

Dementia is not a single disease but a syndrome caused by multiple conditions that damage the brain over time, with Alzheimer’s disease contributing to an estimated 60–70% of cases. Globally, WHO estimates that 57 million people lived with dementia in 2021 and that there are nearly 10 million new cases each year. Against that backdrop, even modest delays in the onset of dementia—if confirmed—could have meaningful population-level implications for individuals, families, and health systems.​

Scientists are exploring several hypotheses for how shingles vaccination might connect to brain health, including reduced viral reactivation, lowered inflammation, and broader immune-system effects that go beyond the targeted infection. However, researchers caution that mechanisms remain unclear, and dementia biology is complex—so results should not be interpreted as proof that a vaccine prevents Alzheimer’s disease specifically.​

What this means for patients now

Public health guidance still positions shingles vaccination primarily as protection against shingles and its complications—not as a dementia-prevention intervention. In the US, CDC recommends two doses of recombinant zoster vaccine (Shingrix) for immunocompetent adults aged 50 and older, typically separated by 2–6 months. CDC also recommends two doses for adults aged 19 and older who are or will be immunodeficient or immunosuppressed, and notes that some may benefit from a shorter 1–2 month interval to complete the series sooner.​

CDC notes that Zostavax is no longer available for use in the United States (as of November 18, 2020), and it advises waiting at least eight weeks after a patient received Zostavax before giving Shingrix. For readers, the most actionable step is still to follow current vaccination recommendations based on age and health status, while watching for future guidance if clinical trials and additional studies confirm a true dementia-risk benefit.​

Key studies at a glance

What comes next

Researchers and clinicians are likely to look for three things: replication across more health systems, clearer biological explanations, and evidence that the relationship holds across vaccine types and subgroups. The Wales study design strengthens the case beyond simple correlation, but it does not replace randomized clinical trials tailored to cognitive outcomes. For now, the most responsible interpretation is that shingles vaccination may have an added potential benefit—while its established benefit remains prevention of shingles and related complications.​